Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon
Michel
M
Neurology Service, University Hospital of Geneva, Rue Micheli-du-Crest 24, CH-1211 Geneva, Switzerland. michel.chofflon@hcuge.ch
Ben-Amor
Ali Frederic
AF
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006031:Glycosylation; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000494:pharmacology*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a